NICE issues Remicade, Orencia decisions

The U.K.'s NICE issued guidance recommending against Remicade infliximab from Schering-Plough (NYSE:SGP) to treat subacute manifestations of moderately to severely active ulcerative colitis (UC). The appraisal can be found at http://www.nice.org.uk/guidance/index.jsp?action=byID&o=11959

In January, NICE recommended for the use of Remicade to treat plaque psoriasis in patients where the disease is very severe. Johnson & Johnson (NYSE:JNJ) markets Remicade in the U.S. (See BioCentury Extra, Thursday, Jan. 24, 2008). ...